NanoBio Corporation to Present Data on its Novel Nanoemulsion-based Vaccine Adjuvant Platform at the World Influenza Congress

ANN ARBOR, Mich.--(BUSINESS WIRE)--NanoBio Corporation announced today that its CEO and Founder, James R. Baker, Jr., M.D., will present new data from studies of its nanoemulsion-based adjuvant platform during the World Influenza Congress, taking place from December 7-9, 2009 in Brussels, Belgium. The presentation details are as follows:

MORE ON THIS TOPIC